10.11.18
Noramco, a provider of controlled substances, is adding commercial-scale capacity of dronabinol (THC) at its Athens, GA, facility. The expansion will support demand for the company’s highly pure cannabidiol (CBD) and dronabinol (THC) analogs of cannabis sativa.
Following implementation, Noramco will supply both THC and CBD from facilities in the U.S. and Europe.
“Today’s announcement is further evidence that our pharmaceutical and healthcare customers place a significant value on our high-purity products and a fully redundant supply chain for cannabidiol and dronabinol,” said Bill Grubb, vice president of business development and Innovation, Noramco.
Clinical samples will be available from the Athens site in 2018, with commercial production commencing in 1Q19. Both dronabinol in oil and dronabinol in ethanol are available in Athens. Previously, the company produced these products only in Europe.
“Providing a manufacturing process that is identical in both Europe and the United States, we now offer pharmaceutical customers the option to source our highly pure product from one or both facilities. The Athens site, which already supplies other high-potency parenteral actives commercially, is a world-class cGMP facility ideally suited for products like dronabinol in oil, or ethanol,” Grubb added.
Following implementation, Noramco will supply both THC and CBD from facilities in the U.S. and Europe.
“Today’s announcement is further evidence that our pharmaceutical and healthcare customers place a significant value on our high-purity products and a fully redundant supply chain for cannabidiol and dronabinol,” said Bill Grubb, vice president of business development and Innovation, Noramco.
Clinical samples will be available from the Athens site in 2018, with commercial production commencing in 1Q19. Both dronabinol in oil and dronabinol in ethanol are available in Athens. Previously, the company produced these products only in Europe.
“Providing a manufacturing process that is identical in both Europe and the United States, we now offer pharmaceutical customers the option to source our highly pure product from one or both facilities. The Athens site, which already supplies other high-potency parenteral actives commercially, is a world-class cGMP facility ideally suited for products like dronabinol in oil, or ethanol,” Grubb added.
